MediWound (NASDAQ: MDWD) is one of 45 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it compare to its peers? We will compare MediWound to similar companies based on the strength of its analyst recommendations, dividends, profitability, risk, institutional ownership, earnings and valuation.
Volatility & Risk
MediWound has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. Comparatively, MediWound’s peers have a beta of 1.29, indicating that their average share price is 29% more volatile than the S&P 500.
Insider and Institutional Ownership
19.6% of MediWound shares are owned by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 14.9% of shares of all “Biopharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares MediWound and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|MediWound||$2.17 million||-$16.18 million||-6.60|
|MediWound Competitors||$579.30 million||$241.72 million||-6.54|
MediWound’s peers have higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent recommendations for MediWound and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
MediWound currently has a consensus price target of $10.00, indicating a potential upside of 102.02%. As a group, “Biopharmaceuticals” companies have a potential upside of 5.39%. Given MediWound’s stronger consensus rating and higher probable upside, equities analysts clearly believe MediWound is more favorable than its peers.
This table compares MediWound and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
MediWound peers beat MediWound on 8 of the 12 factors compared.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.